Metabolic phenotyping in clinical and surgical environments

Nature

Volumn 491, Issue 7424, 2012, Pages 384-392

  Nicholson, Jeremy K ^a   Holmes, Elaine ^a   Kinross, James M ^a   Darzi, Ara W ^a   Takats, Zoltan ^a   Lindon, John C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL COMPOSITION; DISEASE SEVERITY; METABOLISM; MOLECULAR ANALYSIS; PHENOTYPE; SAMPLING;

ASTHMA; BARIATRIC SURGERY; BLOOD; BODY FLUID; CHEMOMETRIC ANALYSIS; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CROHN DISEASE; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; FECES; HUMAN; INFORMATION; METABOLIC PHENOTYPING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE; PHYSICAL CHEMISTRY; PLASMA; POPULATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; STOCHASTIC MODEL; SURGERY; TISSUES; URINE;

ANIMALS; BIOLOGICAL MARKERS; BODY FLUIDS; CELLS; GENERAL SURGERY; HUMANS; INDIVIDUALIZED MEDICINE; METABOLIC DISEASES; METABOLOME; PHENOTYPE;

EID: 84869049715     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature11708     Document Type: Review

References (100)

1. Mirnezami, R., Nicholson, J. & Darzi, A. Preparing for precision medicine. N. Engl. J. Med. 366, 489-491 (2012).
2. Gavaghan, C. L., Holmes, E., Lenz, E., Wilson, I. D. & Nicholson, J. K. An NMR-based metabonomic approach to investigate the biochemical consequences of genetic strain differences: application to the C57BL10J and Alpk:ApfCD mouse. FEBS Lett. 484, 169-174 (2000).
3. Holmes, E. et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 453, 396-400 (2008).
4. Holmes, E., Wilson, I. D. & Nicholson, J. K. Metabolic phenotyping in health and disease. Cell 134, 714-717 (2008).
5. Nicholson, J. K. & Lindon, J. C. Systems biology: metabonomics. Nature 455, 1054-1056 (2008).
6. Fiehn, O. Metabolomics-the link between genotypes and phenotypes. Plant Mol. Biol. 48, 155-171 (2002).
7. Nicholson, J. K., Lindon, J. C. & Holmes, E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29, 1181-1189 (1999).
8. Nicholson, J. K. & Wilson, I. D. Understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nature Rev. Drug Discov. 2, 668-676 (2003).
9. Holmes, E. et al. Nuclear magnetic resonance spectroscopy and pattern recognition analysis of the biochemical processes associated with the progression of and recovery from nephrotoxic lesions in the rat induced by mercury(ii) chloride and 2-bromoethanamine. Mol. Pharmacol. 42, 922-930 (1992).
10. Loscalzo, J., Kohane, I. & Barabasi, A. L. Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Mol. Syst. Biol. 3, 124 (2007).
11. Tomlins, A. M. et al. High resolution 1H NMR spectroscopic studies on dynamic biochemical processes in incubated human seminal fluid samples. Biochim. Biophys. Acta 1379, 367-380 (1998).
12. Patterson, A. D. et al. Metabolomics reveals attenuation of the SLC6A20 kidney transporter in nonhuman primate and mouse models of type 2 diabetes mellitus. J. Biol. Chem. 286, 19511-19522 (2011).
13. Robertson, D. G., Reily, M. D. & Baker, J. D. Metabonomics in pharmaceutical discovery and development. J. Proteome Res. 6, 526-539 (2007).
14. Trygg, J., Holmes, E. & Lundstedt, T. Chemometrics in metabonomics. J. Proteome Res. 6, 469-479 (2007).
15. Nevedomskaya, E., Mayboroda, O. A. & Deelder, A. M. Cross-platform analysis of longitudinal data in metabolomics. Mol. Biosyst. 7, 3214-3222 (2011).
16. Nicholson, J. K. et al. Proton-nuclear-magnetic-resonance studies of serum, plasma and urine from fasting normal and diabetic subjects. Biochem. J. 217, 365-375 (1984).
17. Iles, R. A., Snodgrass, G. J., Chalmers, R. A. & Stacey, T. E. Rapid screening of metabolic diseases by proton NMR. Lancet 2, 1221-1222 (1984).
18. Suhre, K. et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS ONE 5, e13953 (2010).
19. Makinen, V. P. et al. 1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death. Mol. Syst. Biol. 4, 167 (2008).
20. Salek, R. M. et al. A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human. Physiol Genomics 29, 99-108 (2007).
21. Oresic, M. et al. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J. Exp. Med. 205, 2975-2984 (2008).
22. Wang, T. J. et al. Metabolite profiles and the risk of developing diabetes. Nature Med. 17, 448-453 (2011).
23. Friedrich, N. Metabolomics in diabetes research. J. Endocrinol. 215, 29-42 (2012).
24. Howells, S. L. Maxwell, R. J. Griffiths, J. R. Classification of tumour 1H NMR spectra by pattern recognition. NMR Biomed. 5, 59-64 (1992).
25. Fan, L. et al. Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform. Acta Oncol. 51, 473-479 (2012).
26. Garcia, E. et al. Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe. J. Proteome Res. 10, 1765-1771 (2011).
27. Carrola, J. et al. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. J. Proteome Res. 10, 221-230 (2011).
28. Gaudet, M. M. et al. Analysis of serum metabolic profiles in women with endometrial cancer and controls in a population-based case-control study. J. Clin. Endocrinol. Metab. 97, 3216-3223 (2012).
29. Ganti, S. et al. Urinary acylcarnitines are altered in human kidney cancer. Int. J. Cancer 130, 2791-2800 (2012).
30. Nishiumi, S. et al. A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS ONE 7, e40459 (2012).
31. Slupsky, C. M. et al. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin. Cancer Res. 16, 5835-5841 (2010).
32. Lin, L. et al. LC-MS based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery. J. Proteome Res. 10, 1396-1405 (2011).
33. Oakman, C. et al. Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods. Ann. Oncol. 22, 1295-1301 (2011).
34. Tenori, L. et al. Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study. Mol. Oncol. 6, 437-444 (2012).
35. Griffin, J. L. & Shockcor, J. P. Metabolic profiles of cancer cells. Nature Rev. Cancer 4, 551-561 (2004).
36. Tennant, D. A., Durán, R. V. & Gottlieb, E. Targeting metabolic transformation for cancer therapy. Nature Rev. Cancer 10, 267-277 (2010).
37. Spratlin, J. L., Serkova, N. J. & Eckhardt, S. G. Clinical applications of metabolomics in oncology: a review. Clin. Cancer Res. 15, 431-440 (2009).
38. Griffin, J. L., Atherton, H., Shockcor, J. P. & Atzori, L. Metabolomics as a tool for cardiac research. Nature Rev. Cardiol. 8, 630-643 (2011).
39. Shah, S. H. et al. Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease. Am. Heart J. 163, 844-850 (2012).
40. Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57-63 (2011).
41. Caldeira, M. et al. Profiling allergic asthma volatile metabolic patterns using a headspace-solid phase microextraction/gas chromatography based methodology. J. Chromatogr. A 1218, 3771-3780 (2011).
42. Fens, N. et al. Exhaled air molecular profiling in relation to inflammatory subtype and activity in COPD. Eur. Respir. J. 38, 1301-1309 (2009).
43. Saude, E. J. et al. Metabolomic profiling of asthma: diagnostic utility of urine nuclear magnetic resonance spectroscopy. J. Allergy Clin. Immunol. 127, 757-764 (2011).
44. Ubhi, B. K. et al. Metabolic profiling detects biomarkers of protein degradation in COPD patients. Eur. Respir. J. 40, 345-355 (2012).
45. Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59-65 (2010).
46. Yatsunenko, T. et al. Human gut microbiome viewed across age and geography. Nature 486, 222-227 (2012).
47. Nicholson, J. K. et al. Host-gut microbiota metabolic interactions. Science. 336, 1262-1267 (2012).
48. Ooi, M. et al. GC/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis. Inflamm. Res. 60, 831-840 (2011).
49. Williams, H. R. et al. Characterization of inflammatory bowel disease with urinary metabolic profiling. Am. J. Gastroenterol. 104, 1435-1444 (2009).
50. Marchesi, J. R. et al. Rapid and non-invasive metabonomic characterization of inflammatory bowel disease. J. Proteome Res. 6, 546-551 (2007).
51. Li, M. et al. Symbiotic gut microbes modulate human metabolic phenotypes. Proc. Natl Acad. Sci. USA 105, 2117-2122 (2008).
52. Hooper, L. V., Littman, D. R. & Macpherson, A. J. Interactions between the microbiota and the immune system. Science 336, 1268-1273 (2012).
53. Swann, J. R. et al. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc. Natl Acad. Sci. USA 108, 4523-4530 (2011).
54. Holmes, E. et al. Therapeutic modulation of microbiota-host metabolic interactions. Sci. Transl. Med. 4, 137rv6 (2012).
55. Muccioli, G. G. et al. The endocannabinoid system links gut microbiota to adipogenesis. Mol. Syst. Biol. 6, 392 (2010).
56. Yap, I. K. et al. Urinary metabolic phenotyping differentiates children with autism from their unaffected siblings and age-matched controls. J. Proteome Res. 9, 2996-3004 (2010).
57. Evans, C. et al. Altered amino acid excretion in children with autism. Nutr. Neurosci. 11, 9-17 (2008).
58. Thomas, E. L. et al. Aberrant adiposity and ectopic lipid deposition characterize the adult phenotype of the preterm infant. Pediatr. Res. 70, 507-512 (2011).
59. Gordon J. I. Honor thy gut symbionts: redux. Science 336, 1251-1253 (2012).
60. Jia, W., Li, H., Zhao, L. & Nicholson, J. K. Gut microbiota: a potential new territory for drug targeting. Nature Rev. Drug Discov. 7, 123-129 (2008).
61. Kinross, J. M., Holmes, E., Darzi, A. W. & Nicholson, J. K. Metabolic phenotyping for monitoring surgical patients. Lancet 377, 1817-1819 (2011).
62. Clayton, T. A. et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440, 1073-1077 (2006).
63. Clayton, T. A., Baker, D., Lindon, J. C., Everett, J. R. & Nicholson, J. K. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc. Natl Acad. Sci. USA 106, 14728-14733 (2009).
64. Backshall, A., Sharma, R., Clarke, S. J. & Keun, H. C. Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. Clin. Cancer Res. 17, 3019-3028 (2011).
65. Schmerler, D. et al. Targeted metabolomics for discrimination of systemic inflammatory disorders in critically ill patients. J. Lipid Res. 53, 1369-1375 (2012).
66. Cohen, M. J., Serkova, N. J., Wiener-Kronish, J., Pittet, J. F. & Niemann, C. U. 1H-NMR-based metabolic signatures of clinical outcomes in trauma patients-beyond lactate and base deficit. J. Trauma 69, 31-40 (2010).
67. Polinder, S., Haagsma, J. A., Toet, H. & van Beeck, E. F. Epidemiological burden of minor, major and fatal trauma in a national injury pyramid. Br. J. Surg. 99, 114-121 (2012).
68. Alverdy, J. C., Laughlin, R. S. & Wu, L. Influence of the critically ill state on host-pathogen interactions within the intestine: gut-derived sepsis redefined. Crit. Care Med. 31, 598-607 (2003).
69. Volkert, D., Saeglitz, C., Gueldenzoph, H., Sieber, C. C. & Stehle, P. Undiagnosed malnutrition and nutrition-related problems in geriatric patients. J. Nutr. Health Aging 14, 387-392 (2010).
70. Fitzgerald, S. P. & Bean, N. G. An analysis of the interactions between individual comorbidities and their treatments - implications for guidelines and polypharmacy. J. Am. Med. Dir. Assoc. 11, 475-484 (2010).
71. Shah, A. A. et al. Metabolic profiles predict adverse events after coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg. 143, 873-878 (2012).
72. Mao, H. et al. Systemic metabolic changes of traumatic critically ill patients revealed by an NMR-based metabonomic approach. J. Proteome Res. 8, 5423-5430 (2009).
73. Chen, J. et al. Metabonomics study of the acute graft rejection in rat renal transplantation using reversed-phase liquid chromatography and hydrophilic interaction chromatography coupled with mass spectrometry. Mol. Biosyst. 8, 871-878 (2012).
74. Kim, C. D. et al. Metabonomic analysis of serum metabolites in kidney transplant recipients with cyclosporine A- or tacrolimus-based immunosuppression. Transplantation 90, 748-756 (2010).
75. Legido-Quigley, C. et al. Bile UPLC-MS fingerprinting and bile acid fluxes during human liver transplantation. Electrophoresis 32, 2063-2070 (2011).
76. Girlanda, R. et al. Metabolomics of human intestinal transplant rejection. Am. J. Transplant. http://dx.doi.org/10.1111/j.1600-6143.2012.04183.x (July 2012).
77. Fornari, F., Comis, V. R. & Lisboa, H. R. Bariatric surgery or medical therapy for obesity. N. Engl J. Med. 367, 474 (2012).
78. Li, J. V. et al. Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut 60, 1214-1223 (2011).
79. Mutch, D. M. et al. Metabolite profiling identifies candidate markers reflecting the clinical adaptations associated with Roux-en-Y gastric bypass surgery. PLoS ONE 4, e7905 (2009).
80. Zhang, H. et al. Human gut microbiota in obesity and after gastric bypass. Proc. Natl Acad. Sci. USA 106, 2365-2370 (2009).
81. Biagi, E., Candela, M., Fairweather-Tait, S., Franceschi, C. & Brigidi, P. Aging of the human metaorganism: the microbial counterpart. Age (Dordr.) 34, 247-267 (2012).
82. Claesson, M. J. et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 488, 178-184 (2012).
83. Jeevan, R. et al. Reoperation rates after breast conserving surgery for breast cancer among women in England: retrospective study of hospital episode statistics. Br. Med. J. 345, e4505 (2012).
84. Chan, E. C. et al. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J. Proteome Res. 8, 352-361 (2009).
85. Opstad, K. S., Bell, B. A., Griffiths, J. R. & Howe, F. A. An investigation of human brain tumour lipids by high-resolution magic angle spinning 1H MRS and histological analysis. NMR Biomed. 21, 677-685 (2008).
86. Wright, A. J. et al. Ex-vivo HRMAS of adult brain tumours: metabolite quantification and assignment of tumour biomarkers. Mol. Cancer 9, 66 (2010).
87. Wu, C. L. et al. Metabolomic imaging for human prostate cancer detection. Sci. Transl. Med. 2, 16ra18 (2010).
88. Bertilsson, H. et al. Changes in gene transcription underlying the aberrant citrate and choline metabolism in human prostate cancer samples. Clin. Cancer Res. 18, 3261-3269 (2012).
89. McDonnell, L. A. & Heeren, R. M. Imaging mass spectrometry. Mass Spectrom. Rev. 26, 606-643 (2007).
90. Balog, J. et al. Identification of biological tissues by rapid evaporative ionization mass spectrometry. Anal. Chem. 82, 7343-7350 (2010).
91. Guenther, S. et al. Electrospray post-ionization mass spectrometry of electrosurgical aerosols. J. Am. Soc. Mass Spectrom. 22, 2082-2089 (2011).
92. Gerbig, S. et al. Analysis of colorectal adenocarcinoma tissue by desorption electrospray ionization mass spectrometric imaging. Anal. Bioanal. Chem. 403, 2315-2325 (2012).
93. Schafer, K. C. et al. Real time analysis of brain tissue by direct combination of ultrasonic surgical aspiration and sonic spray mass spectrometry. Anal. Chem. 83, 7729-7735 (2011).
94. Beckonert, O. et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nature Protocal. 2, 2692-2703 (2007).
95. Lindon, J. C. & Nicholson, J. K. Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. Annu. Rev. Anal. Chem. 1, 45-69 (2008).
96. Wong, A. et al. Evaluation of high resolution magic-angle coil spinning NMR spectroscopy for metabolic profiling of nanoliter tissue biopsies. Anal. Chem. 84, 3843-3848 (2012).
97. Jellum, E. et al. Application of glass capillary-column gas chromatography-mass spectrometry to the studies of human diseases. J. Chromatogr. 126, 487-493 (1976).
98. Ramautar, R., Mayboroda, O. A., Somsen, G. W. & de Jong, G. J. CE-MS for metabolomics: developments and applications in the period 2008-2010. Electrophoresis 32, 52-65 (2011).
99. Crockford, D. J. et al. Statistical heterospectroscopy, an approach to the integrated analysis of NMR and UPLC-MS data sets: application in metabonomic toxicology studies. Anal. Chem. 78, 363-371 (2006).
100. Fonville, J. M. et al. Robust data processing and normalization strategy for MALDI mass spectrometric imaging. Anal. Chem. 84, 1310-1319 (2012).